Healthcare Market Updates | BioTuesdays by Kilmer Lucas IR

Markets

HCW ups AVEO Pharma to buy; PT to $1.75 from $1

H.C. Wainwright upgraded AVEO Pharmaceuticals (NASDAQ:AVEO) to “buy” from “neutral” and raised its price target to $1.75 from $1, citing a positive overall survival (OS) update from the Phase 3 TIVO-3 study of tivozanib...

September 11, 2019

Markets

Janney starts Spero Therapeutics at buy; fair value estimate $27

Janney Montgomery Scott initiated coverage of Spero Therapeutics (NASDAQ:SPRO) with a “buy” rating and fair value estimate of $27. The stock closed at $9.98 on Sept. 6. Analyst Esther Hong writes that her initiation is...

September 9, 2019

Markets

Janney starts Eloxx Pharma at buy; fair value estimate $14

Janney launched coverage of Eloxx Pharmaceuticals (NASDAQ:ELOX) with a “buy” rating and fair value estimate of $14. The stock closed at $5.97 on Sept. 5. Eloxx’s pipeline is focused on genetic diseases caused by...

September 6, 2019

Markets

SVB Leerink cuts Mallinckrodt PT to $2 from $7

SVB Leerink reduced its price target for “market perform” rated Mallinckrodt (NYSE:MNK) to $2 from $7, reflecting a higher risk profile for the company. The stock closed at $1.59 on Sept. 5. “While we believe that the...

September 6, 2019

Markets

HCW starts Corcept Therapeutics at buy; PT $18

H.C. Wainwright launched coverage of Corcept Therapeutics (NASDAQ:CORT) with a “buy” rating and $18 price target. The stock closed at $12.59 on Sept. 5. Corcept is focused on development and commercialization of...

September 6, 2019

Markets

Janney starts Applied Genetic Technologies at buy; fair value estimate $13

Janney initiated coverage of Applied Genetic Technologies (NASDAQ:AGTC) with a “buy” rating and fair value estimate of $13. The stock closed at $3.20 on Sept. 5. “We see a highly attractive investment opportunity in...

September 6, 2019

Markets

Stereotaxis to uplist to NYSE American

The common shares of Stereotaxis (OTCQX:STXS) were approved for listing on the NYSE American exchange, effective with the opening on Sept. 6, with the same stock symbol. They will trade on the OTCQX until the close on...

September 5, 2019

Markets

HCW cuts Tetraphase Pharma to neutral and removes PT

H.C. Wainwright downgraded Tetraphase Pharmaceuticals (NASDAQ:TTPH) to “neutral” from “buy” and removed its price target, citing an early debt payoff that substantially increases the company’s risk. The stock closed at...

September 3, 2019

Markets

AGP starts coverage of Itamar Medical at buy; PT $15.50

Alliance Global Partners initiated coverage of Itamar Medical (NASDAQ:ITMR) with a “buy” rating and $15.50 price target. The stock closed at $9.10 on Aug. 29. “We see Itamar as the technology leader in home sleep...

August 30, 2019

Markets

Stifel ups Tabula Rasa HealthCare to buy; PT to $75 from $70

Stifel upgraded Tabula Rasa HealthCare (NASDAQ:TRHC) to “buy” from “hold” and raised its price target to $75 from $70, citing an “improving risk/reward with a favorable fundamental backdrop.” The stock closed at $57.64...

August 30, 2019

HCW ups AVEO Pharma to buy; PT to $1.75 from $1

Janney starts Spero Therapeutics at buy; fair value estimate $27

Janney starts Eloxx Pharma at buy; fair value estimate $14

SVB Leerink cuts Mallinckrodt PT to $2 from $7

HCW starts Corcept Therapeutics at buy; PT $18

Janney starts Applied Genetic Technologies at buy; fair value estimate $13

Stereotaxis to uplist to NYSE American

HCW cuts Tetraphase Pharma to neutral and removes PT

AGP starts coverage of Itamar Medical at buy; PT $15.50

Stifel ups Tabula Rasa HealthCare to buy; PT to $75 from $70

Follow Us

Subscribe

General

More

Subscribe